Archive for the ‘Gene Therapy Research’ Category

FAQ-8 of 19: With Stem Cell Therapy Are There Any Stem Cell Side Effects?
youtu.be The near-miraculous effects of stem cell treatments, when applied by qualified, licensed medical practitioners, is even more wonderful precisely because there are almost no known ill effects or side effects. So for more detailed and personalized information, go to StemCell-Asia.info to learn more on the Apply Now page httpFrom:John PepperViews:0 0ratingsTime:00:53More inPeople Blogs

Go here to read the rest:
FAQ-8 of 19: With Stem Cell Therapy Are There Any Stem Cell Side Effects? - Video

FAQ-7 of 19: With Stem Cells, How Long Do Stem Cell Therapy Benefits Last?
youtu.be Briefly explaining how long the benefits of stem cell therapy last, when, why and for what conditions. For more detailed explanations, go to StemCell-Asia.info and find the #39;Apply Now #39; page, httpFrom:John PepperViews:0 0ratingsTime:01:19More inNonprofits Activism

Read the original here:
FAQ-7 of 19: With Stem Cells, How Long Do Stem Cell Therapy Benefits Last? - Video

FAQ-9 of 19: In Stem Cell Therapy Are There Any Contraindications for Stem Cells?
youtu.be There ARE some times and ways that stem cells should NOT be used, and this short video outlines them. For more personalized information, visit bit.ly or StemCell-Asia.info now.From:John PepperViews:0 0ratingsTime:00:54More inEducation

Read more:
FAQ-9 of 19: In Stem Cell Therapy Are There Any Contraindications for Stem Cells? - Video

FAQ-7 of 19: In Stem Cell Therapy How Long Do Benefits of Stem Cells Last?
youtu.be Briefly explaining how long the benefits of stem cell therapy last, when, why and for what conditions. For more detailed explanations, go to StemCell-Asia.info and find the #39;Apply Now #39; page, httpFrom:Harvey WallbangerViews:0 0ratingsTime:01:19More inEducation

Continue reading here:
FAQ-7 of 19: In Stem Cell Therapy How Long Do Benefits of Stem Cells Last? - Video

FAQ-8 of 19: Do Stem Cells Have Side Effects In Stem Cell Therapy?
youtu.be The near-miraculous effects of stem cell treatments, when applied by qualified, licensed medical practitioners, is even more wonderful precisely because there are almost no known ill effects or side effects. So for more detailed and personalized information, go to StemCell-Asia.info to learn more on the Apply Now page httpFrom:Karridine1Views:0 0ratingsTime:00:53More inPeople Blogs

Here is the original post:
FAQ-8 of 19: Do Stem Cells Have Side Effects In Stem Cell Therapy? - Video

FAQ-7 of 19: With Stem Cell Therapy, How Long Do Stem Cell Benefits Last?
youtu.be Briefly explaining how long the benefits of stem cell therapy last, when, why and for what conditions. For more detailed explanations, go to StemCell-Asia.info and find the #39;Apply Now #39; page, httpFrom:Karridine1Views:0 0ratingsTime:01:19More inPeople Blogs

View original post here:
FAQ-7 of 19: With Stem Cell Therapy, How Long Do Stem Cell Benefits Last? - Video

FAQ-9 of 19: In Stem Cell Therapy Are There Contraindications for Stem Cells?
youtu.be Yes, there ARE some times and some ways that stem cells should NOT be used, so this short video outlines them for you. For more personalized information, visit bit.ly or StemCell-Asia.info now.From:Karridine1Views:0 0ratingsTime:00:54More inPeople Blogs

Go here to read the rest:
FAQ-9 of 19: In Stem Cell Therapy Are There Contraindications for Stem Cells? - Video

NEW YORK, Oct. 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that Company management and management of its subsidiary, Progenitor Cell Therapy ("PCT"), have been invited to present at multiple conferences in November.

American Heart Association -- Scientific Sessions 2012

2012 ISPE Annual Meeting: Global GMP Solutions through Innovation and Transformation

Lazard Capital Markets 9th Annual Healthcare Conference

New York Society of Security Analysts' 16th Annual "Investing in Life Sciences" Conference

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

Read more here:
NeoStem to Present at Multiple Conferences in November

By Philip C. Tubeza Philippine Daily Inquirer

Stem cell therapy might provide a remedy for acquired immunodeficiency syndrome (AIDS) after it was used on an HIV patient in Germany, the first person known to have been cured of the disease, a Department of Health (DOH) official said Tuesday.

Dr. Gerald Belimac, program manager of the DOH National AIDS/Sexually Transmitted Infection Prevention and Control Program, said American Timothy R. Brown, the so-called Berlin Patient who had been infected with the human immunodeficiency virus, was cured after getting stem cells in 2007 from a donor who was genetically resistant to the virus that caused AIDS.

However, he said that this procedure was very complex and was still under study.

It takes the right person, the right recipient, the right donor, for a stem cell transplantation particularly on HIV to be successful, Belimac said.

If it comes from other donors, there is really a high chance that the recipient would reject it, she added.

Brown was infected with HIV in 1995 and was later diagnosed with leukemia, or cancer of the blood.

He underwent a transplant of stem cells for the leukemia and it turned out that those stem cells had genes that were resistant to HIV, Belimac said.

Medical research has shown that almost 5 percent of Caucasians are genetically resistant to HIV, he said, but there are still no studies showing Filipinos having similar genes.

Read more:
A first: Stem cell therapy cures HIV patient in Germany

MANILA, Philippines Amid the recent warning issued by the Department of Health (DOH) regarding stem cell therapy, doctors who are offering the treatment in the Philippines clarified that they are not promising a cure.

We are very careful about claiming cure. These days ang dami nagsasalita, nawala ang sakit. All of a sudden siya (stem cell therapy) na yung magic bullet ng buong mundo, like if you get stem cell, you get cured, said Dr. Michelle de Vera, deputy director of the Institute of Personalized Molecular Medicine at The Medical City.

Kapag may narinig na ganyan dapat lalo silang mag-ingat. Cure is zero evidence of disease or kung genetic yung disease dapat napalitan yung genes mo. Hindi mangyayari yun at this point," he stressed.

De Vera, an allergologist and immunologist, does stem cell therapy on her patients at The Medical City but he said he believes that the DOH is right in warning patients on stem cell therapy.

Tama naman na magbigay sila ng warning,I think what their trying to do is regulate stem cell therapy, the doctor said.

Public advisory

The DOH recently came out with a public advisory on stem cell therapies saying that there is an "observed proliferation of centers offering stem cell treatments for medical and aesthetic purpose, and although this technology holds promise, stem cell therapy is not yet part of the standard of care and is considered an investigative procedure for compassionate use."

The DOH further stated that "applications of stem cells for the treatment of malignancies, blood disorders, degenerative diseases (e.g. Alzhimer's), metaboloc diseases (eg diabetes), and immune cell therapy are still under clinical evaluation and study."

I did not say it doesn't work but it takes a while, a lot of experiments and clinical studies before it is considered a standard of care in medicine, clarified Health Secretary Enrique T. Ona.

Ona also added in his statement that "the public is strongly advised to avoid stem cell therapies which use the following as sources for stem cells: embryonic stem cells, aborted fetuses, genetically-altered and animal fresh cells." Not from animals

Continued here:
Doctors don't promise cure with stem cell therapy

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics (CYTX) today announced two independent investigator-sponsored and funded cell therapy clinical studies in Japan have been approved by the Ministry of Health, Labor and Welfare under the Guidelines on Clinical Research Using Human Stem Cells. One study will investigate the use of Cytoris cell therapy as a treatment for ischemic heart failure and the other as a treatment for cirrhosis of the liver. The studies will be performed by Shuichi Kaneko, M.D., Ph.D., Professor and Chairman of Departments of Gastroenterology, and Disease Control and Hemostasis, Graduate School of Medicine at Kanazawa University Hospital School of Medicine.

In each study, patients will receive an injection of Cytoris cell therapy, which consists of their own adipose-derived stem and regenerative cells (ADRCs) processed at the point-of-care using the Cytoris proprietary and automated Celution System. The ischemic heart failure study will enroll patients with low left ventricular function due to a prior heart attack and the ADRCs will be delivered through the coronary artery. In the study of patients with cirrhosis of the liver, the ADRCs will be delivered through the hepatic artery.

About Cytori

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution system product family. http://www.cytori.com

Read the original post:
Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies Approved in Japan

NEW YORK, Nov. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases)

http://www.reportlinker.com/p01022392/Autologous-Stem-Cell-and-Non-Stem-Cell-Based-Therapies-Market-2012-2017-Neurodegenerative-cardiovascular-cancer--autoimmune-skin-and-infectious-diseases.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Autologous cell therapies are new therapeutic intervention where it introduces or uses cells or tissues from the individual, cultured, expanded and re-introduced at the site of the disease of the donor. They are widely promoted as next pillar or advancement in medical care.

Growth of the market is very rapid especially in regulatory approvals, applications areas and rapid improvements in efficacy of treatment; it has enormous advantages over allogenic stem cell therapies. Autologous transplants are relatively safe procedures, with less rates of complications and infections compared with allogenic transplants. In many instances, much of the procedure can be done on an outpatient basis. It helps in treating various dreadful diseases by transplanting their own body cells where it results in meager chances of transplant rejection.

We have also profiled leading players of this industry with their recent developments and other strategic industry activities. These include: Neostem (U.S.), Tengion (U.S.), Brainstorm Cell Therapeutics (U.S.), Dendreon Corporation (U.S.), Georgia Health Sciences University (U.S.), Regenexx (U.S.), Regeneus (Australia), Cytori Therapeutics (U.S.), Tigenix (Belgium).

Scope of the Report

This research report titled "Autologous Cell Therapy (2012-2017)" provides details about various ACT based treatments and their application areas. Every health regulatory bodies will be expecting companies and universities to develop therapy treatments, which are safer, affordable, robust, rapid, easy to use, effective and deliverable to the end user. ACT treatments for particular application areas it is safe, experiencing robust growth, minimal steps of procedure to follow and rapid in deriving the results. As for now the treatments prices are not affordable, but by the intrusion of government bodies, it will definitely experience a immense market growth.

The report gives a detailed analysis about state of the art of autologous cell therapies. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It also consists of funding details of the innovative therapy and recent activities in terms of mergers & acquisitions of the company, revenue forecasting. It includes latest therapy details and products which are available for licensing and approvals from various regulatory bodies. Using drivers, restraints and challenges it is forecasted for a period of five years i.e. 2012-2017. Opportunity strategy evaluation has been included which gives information for investors.

Autologous Cell Therapy technology is changing the medicinal treatments by introducing various new therapies. Its scope is vast and promising for the future despite challenges.

Link:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer ...

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics (CYTX) today announced that an investigator-sponsored and funded clinical study evaluating Cytoris cell therapy as a potential treatment for limited and diffuse cutaneous systemic sclerosis (scleroderma) has been approved to begin in France by the National Agency for the Safety of Medicines and Health Products (ANSM, formerly AFSSAPS). The study will be conducted by Professor Guy Magalon, M.D., Chief of the Division of Plastic Surgery and Professor of Universities, at Hpital de la Conception, AP-HM Marseille, France, Professor Brigitte Granel, M.D., Department of Internal Medicine of Hospital Nord and Professor of Universities, and Professor Florence Sabatier, M.D., Head of the Department of Cell Therapy.

We are interested in investigating Cytoris cell therapy as a potential treatment for scleroderma because earlier data suggest it can improve blood flow and minimize the immune response, said Professor Magalon. Based on these properties, the treatment has the potential to reverse the ischemic effects, where there is tightening of the arteries in the affected areas, and counter the autoimmune reaction. While this research is in its early stages, if we begin to observe encouraging efficacy, we intend to expand the trial to include more hospitals and patients.

Per the study protocol, 13 patients will receive an injection of their own adipose-derived stem and regenerative cells (ADRCs) into the affected areas of their fingers. ADRCs will be processed using Cytoris automated Celution System so that their own cells may be redelivered immediately. The primary endpoints are safety and the improvement in function of the hands, as measured by the Cochin hand functional scale at six months. Secondary endpoints include severity of pain visual analog scale, Systemic Sclerosis Health Assessment Questionnaire, Rodnan score adapted to the hand, HAMIS test, and severity of the Raynauds syndrome. The first patient in the study is expected to be treated in November 2012.

Scleroderma is a rare autoimmune disorder that results in an overproduction of collagen in the skin and vital organs. It ranges from mild to severe, is typically detected between the ages of 40 and 50, and it affects women four times more frequently than men. It is classified as localized or systemic. Two forms of systemic sclerosis include limited cutaneous and diffuse cutaneous, depending on the extent of skin fibrosis. In both subgroups, skin fibrosis affects the hands and leads to disability. Combined prevalence for limited and diffuse cutaneous systemic scleroderma in the G6 European countries is approximately 42,000 people. It is classified as an orphan disease by Orphanet, a European consortium on rare diseases.

The study is being organized by a multidisciplinary team of researchers at Hpital de le Conception. The researchers include Julie Veran, Cell Manufacturing Manager, Laurent Giraudo, Laboratory Chief Assistant, and Laurent Arnaud, Cell Characterization responsible, of the Cell Therapy Department. In addition, Aurelie Daumas, Chief Clinician Assistant from the Department of Internal Medicine, and Pierre Nguyen, M.D., Chief Clinician Assistant from the Department of Plastic & Reconstructive Surgery, will support implementation of the study. Per the request of the ANSM, the Department of Cell Therapy had previously validated the cell characterization, viability and reproducibility of the ADRCs processed by the Celution System.

About Cytori Therapeutics

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution System product family. http://www.cytori.com

Visit link:
Investigator-Sponsored Cell Therapy Clinical Study for Scleroderma Initiated in France

By Erika Sauler Philippine Daily Inquirer

MANILA, Philippines This type of stem cell therapy does not claim to be the fountain of youth, but an alternative treatment to arthritis, muscle pain and tendon tear.

Two Filipino doctors who trained in the United States said in a media forum on Sunday that autologous stem cell therapy could speed up the healing of musculoskeletal and sports-related injuries, which could be an optional remedy before undergoing surgery.

Dr. Jeimylo de Castro explained that the procedure would involve taking stem cells from the patients blood, fat tissue or bone marrow and injecting them to the injured area of the same person. This type of therapy is different from the controversial embryonic stem cells which are harvested from animals or fertilized eggs.

With stem cell therapy being a current fad for anti-aging, the Department of Health has warned the public that the benefits of stem cell therapy are still under evaluation. The DOH will soon issue guidelines for the use of stem cell therapy and the licensing of facilities offering this service.

De Castro and Dr. Franklin Domingo are both fellows of the Philippine Academy of Rehabilitation Medicine. They underwent training for stem cell therapy under Dr. Joseph Purita of the Institute of Regenerative and Molecular Orthopaedics, and Dr. Sherwin Kevy of Harvards Immune Disease Institute.

If you have arthritis and you take anti-inflammatory drugs, you will not feel the pain so you will move around and further damage the cartilage. Whereas stem cells will regenerate tissues and ease the pain, making the damaged cells become young again, De Castro said.

Domingo likened the stem cells to high school students who have no career yet and could be trained to be professionals in a field where they are needed. So if the stem cells are injected into an injured knee, they will develop into tissues that hasten the recovery of the area.

According to Domingo, stem cell therapy is not for everybody and is not a quick-fix solution because it uses the bodys natural ability to heal.

Patients who have cancer and infection are not allowed to undergo stem cell therapy, and so are those under the influence of alcohol or who have taken blood-thinning medicine like Coumadin at the time of extraction.

Read more from the original source:
Stem cell therapy for muscle, sports injury alternative to surgery

MANILA, Philippines Its supposed to cure various illnesses such as cancer, spinal cord injury and Parkinsons disease. Is stem cell therapy the cure-all that it is touted to be?

Health Undersecretary Teodoro Herbosa said it is important to note that stem cell treatments are still at the experimental stage.

"The advisory is very clear. This is still an investigative form of therapy. Anecdotal reports are not enough evidence to say there is treatment, he said in an interview on ANC's Talkback with Tina Palma.

He said there are only two standard stem cell therapies considered effective and acceptable to the medical community.

"To date, I can only name two cases that are considered standard therapy. That is bone marrow transplantation--one for severe cancer, blood cancer and the other one is bone marrow transplantation after chemotherapy for any type of cancer, he said.

Herbosa said the Department of Health cannot confirm yet if stem cell treatment is indeed effective against certain diseases.

Dr. Tranquilino Elicao Jr., an oncologist who availed of the treatment in April in Frankfurt, Germany, said stem cell therapy cured his high blood pressure, sugar, cholesterol and uric acid.

He had 12 injections of cells, which came from lambs.

After a month, I had my blood tests. Everything went down to normal, Elicao said.

Elicao also said he is not taking medication anymore because he has regained his health.

Go here to read the rest:
Stem cell therapy a cure-all? Not so fast

SANTA ANA, Calif.--(BUSINESS WIRE)--

Irvine Scientific, a leading cell culture media/ medical device company for more than 40 years, announced their newly launched cell therapy PRIME-XV product portfolio as part of the companys commitment to accelerate basic research and clinical applications in cell therapy and regenerative medicine. Using their expertise in cell culture media development, PRIME-XV products were designed to function as part of an integrated workflow solution in culturing primary cells, where all products have been pre-validated to decrease end user qualification time. Initially, PRIME-XV products will comprise of a serum-free medium for the expansion of human mesenchymal stromal/ stem cells (MSCs), biopreservation solutions and extracellular matrix proteins. However, Irvine Scientific intends to expand this product line to offer other cell culture media and reagents, such as stem cell qualified fetal bovine serum, tumorsphere and neural progenitor cell expansion media. Examples of existing PRIME-XV products include:

PRIME-XV MatrIS F: a recombinant human matrix protein intended for the culture of human stem/ progenitor cells under serum-free conditions. PRIME-XV MatrIS F provides an alternative substrate to the PRIME-XV Human Fibronectin product, which has a wide variety of applications in primary cell spreading and attachment.

PRIME-XV MSC EXPANSION SFM: a complete, serum-free expansion medium specifically designed for the culture of primary human MSCs derived from bone marrow and adipose tissues. This medium is supplied as a convenient one 250mL bottle and is ready-to-use without the need of additional cytokine/ growth factor supplements. MSCs cultured in PRIME-XV MSC EXPANSION SFM out performed serum-containing medium as well as leading competitors in cell expansion studies without losing their multipotent characteristics or immune modulation functions.

PRIME-XV Hypothermic Biopreservation Solution: a protein-free, defined solution intended for storage and stable shipping of cells and tissue samples under hypothermic (2-8C) condition. By preserving cells above freezing temperature, it reduces cellular stress response associated from chilling and re-warming of cells and tissues, and retains high culture viabilities after recovery. Simply replace the culture medium with this animal component-free, cGMP manufactured product for short term storage. To recover from preservation, PRIME-XV Hypothermic Biopreservation Solution is removed and replaced with growth medium of choice.

As an alternative to the PRIME-XV Hypothermic Biopreservation Solution, Irvine Scientific also carries a protein-free, defined PRIME-XV Cryogenic Preservation Solution, which allows for cryopreservation of biologics at -80C to -196C.

About Irvine Scientific

Irvine Scientific, a member of JX group, is a worldwide leader in the design, manufacture and distribution of medical devices, including Cell Therapy, Industrial Cell Culture, Cytogenetic and Assisted Reproductive Technology products. We are a large scale producer of advanced quality cell culture media for the cell therapy, industrial bioprocess, medical and diagnostic markets. Our companys extensive experience in the design of culture media, compliance with ISO and FDA regulations for class II/III medical devices and industrial scale manufacturing capacity provides our customers with unique capabilities and support. Irvine Scientific delivers products worldwide to the biopharmaceutical industry, research and medical laboratory communities.

For more information:

- Visit http://www.irvinesci.com

Originally posted here:
Irvine Scientific Offers Cell Therapy Products

Courtyard Columbus Downtown Hotel Video
View an official hotel video of the Courtyard Columbus Downtown before your stay, only on Marriott.com. Marriott.com hotel videos include shots of the hotel exterior, hotel rooms, and amenities, fitness and recreation areas, and meeting and event space. Book on Marriott.com today!From:marriotthotelvideosViews:123 0ratingsTime:01:08More inTravel Events

View original post here:
Courtyard Columbus Downtown Hotel Video - Video

Love Never Fails Climb4SMA 2.wmv
This video was made for the Jadon #39;s Hope 2nd Annual Event - Climb4SMA Kickoff Party. Climb4SMA has partnered with the Gwendolyn Strong Foundation to raise money for gene therapy research. What an incredible night it was fighting such a horrible disease.From:50ttownViews:1329 3ratingsTime:03:04More inNonprofits Activism

Originally posted here:
Love Never Fails Climb4SMA 2.wmv - Video

BALIF: David Tsai, Esq.
DAVID TSAI, Esq. Perkins Coie LLP BALIF Co-Chair, 2011 Best Under 40, and 2010 Barrister of the Year David has served as the BALIF Co-Chair for the past year and a half. He is an intellectual property litigator at Perkins Coie LLP in San Francisco and focuses on trade secret and patent litigation involving the Internet, software, semiconductors, smartphones, LEDs, pharmaceuticals, biotechnologies, and medical devices. His interest in technology stems from his prior work as a product manager at internet startups, where he focused on developing platforms for online collaborative communications, and during his time at Stanford, where he helped develop Stanford #39;s first online problem sets (while conducting stem cell gene therapy research). David is currently the Vice President of the Silicon Valley Intellectual Property Law Association (SVIPLA) and also sits on the Board of the Bar Association of San Francisco (BASF). David is fluent in spoken Taiwanese and Chinese Mandarin and represents numerous Taiwan-based companies. David decided to attend law school while driving home to SF from Silicon Valley in 2002. Having already volunteered for Project Open Hand and the San Francisco AIDS Foundation for over three years, David wanted to make a bigger difference for minority communities through the law. While at law school, he spent many afternoons volunteering with the AIDS Legal Services in San Jose and the East Palo Alto Community Law Center. Today, David remains committed to ...From:BALIF SFViews:652 5ratingsTime:04:26More inNonprofits Activism

Read the rest here:
BALIF: David Tsai, Esq. - Video

Bacterial Bioluminescence in the GIT
Bacterial Bioluminescence in the GIT High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting (Movie S1 - journal.pone.0030940.s001.avi): Movie depicting rotational 3D optical tomography in combination with mouse anatomical atlas displaying luminescence in GIT of mice 27 days post oral administration of lux-labelled E. coli MG1655. - Engineered Bacteria Effectively Target Tumors, Enabling Tumor Imaging Potential in Mice Tumor-targeted bioluminescent bacteria have been shown for the first time to provide accurate 3-D images of tumors in mice, further advancing the potential for targeted cancer drug delivery, according to a study published in the Jan. 25 issue of the online journal PLoS ONE. http://www.sciencedaily.com Reference High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting PLoS ONE 7(1): e30940. doi:10.1371/journal.pone.0030940 http://www.plosone.org Abstract The ability to track microbes in real time in vivo is of enormous value for preclinical investigations in infectious disease or gene therapy research. Bacteria present an attractive class of vector for cancer therapy, possessing a natural ability to grow preferentially within tumours following systemic administration. Bioluminescent Imaging (BLI) represents a powerful tool for use with bacteria engineered to express reporter genes such as lux. BLI is traditionally used as a 2D modality resulting in images that are limited in their ability to anatomically ...From:SergeytuleViews:160 0ratingsTime:00:11More inScience Technology

Read the original:
Bacterial Bioluminescence in the GIT - Video

3D Intratumoural Optical and mu;CT Imaging
3D Intratumoural Optical and µCT Imaging High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting (Movie S3 - journal.pone.0030940.s003.mov): Combined µCT and luminescence imaging of subcutaneous HCT116-luc2 tumour colonised by B. breve. Viable tumour (FLuc green/blue), vasculature (contrast agent -- red) and bacterial (orange/yellow) signals are visualised. - Engineered Bacteria Effectively Target Tumors, Enabling Tumor Imaging Potential in Mice Tumor-targeted bioluminescent bacteria have been shown for the first time to provide accurate 3-D images of tumors in mice, further advancing the potential for targeted cancer drug delivery, according to a study published in the Jan. 25 issue of the online journal PLoS ONE. http://www.sciencedaily.com Reference High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting PLoS ONE 7(1): e30940. doi:10.1371/journal.pone.0030940 http://www.plosone.org Abstract The ability to track microbes in real time in vivo is of enormous value for preclinical investigations in infectious disease or gene therapy research. Bacteria present an attractive class of vector for cancer therapy, possessing a natural ability to grow preferentially within tumours following systemic administration. Bioluminescent Imaging (BLI) represents a powerful tool for use with bacteria engineered to express reporter genes such as lux. BLI is traditionally used as a 2D modality resulting in images that are limited in ...From:SergeytuleViews:99 0ratingsTime:00:18More inScience Technology

Link:
3D Intratumoural Optical and μCT Imaging - Video

3D Co-localisation of Tumour And Bacterial Bioluminescence
3D Co-localisation of Tumour And Bacterial Bioluminescence High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting (Movie S2 - journal.pone.0030940.s002.mov): Movie providing tomographic detail of source signal distribution of B. breve lux (green) 10 days post IV administration to mice bearing HCT116 FLuc (orange) expressing tumours. B. breve lux is observed in multiple disparate #39;clusters #39; within the tumour. - Engineered Bacteria Effectively Target Tumors, Enabling Tumor Imaging Potential in Mice Tumor-targeted bioluminescent bacteria have been shown for the first time to provide accurate 3-D images of tumors in mice, further advancing the potential for targeted cancer drug delivery, according to a study published in the Jan. 25 issue of the online journal PLoS ONE. http://www.sciencedaily.com Reference High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting PLoS ONE 7(1): e30940. doi:10.1371/journal.pone.0030940 http://www.plosone.org Abstract The ability to track microbes in real time in vivo is of enormous value for preclinical investigations in infectious disease or gene therapy research. Bacteria present an attractive class of vector for cancer therapy, possessing a natural ability to grow preferentially within tumours following systemic administration. Bioluminescent Imaging (BLI) represents a powerful tool for use with bacteria engineered to express reporter genes such as lux. BLI is traditionally used as a ...From:SergeytuleViews:195 0ratingsTime:00:34More inScience Technology

Read more:
3D Co-localisation of Tumour And Bacterial Bioluminescence - Video

Healthy U - Virotherapy Research
Researchers at LSU Health Shreveport and Washington University in St. Louis are conducting joint research to see if a common cold virus can be used to deliver a #39;suicide gene #39; to wipe out colon cancer.From:LSUHSCShreveportViews:233 1ratingsTime:01:24More inAutos Vehicles

Continued here:
Healthy U - Virotherapy Research - Video

Charged Gold Nanoparticles "Unzip" DNA
Learn more on Zeitnews: Research from North Carolina State University shows that gold nanoparticles with a slight positive charge work collectively to unravel DNA #39;s double helix. This finding has ramifications for gene therapy research and the emerging field of DNA-based electronics. More information available at news.ncsu.eduFrom:ZeitNewsViews:324 7ratingsTime:00:40More inScience Technology

The rest is here:
Charged Gold Nanoparticles "Unzip" DNA - Video

Health | Oregon | Science

OPB | Oct. 24, 2012 4:44 p.m. | Portland, Oregon

Oregon Health & Science University unveiled Wednesday what may be a new gene therapy. The hope is to avoid some dreaded hereditary disorders.

The new therapy was developed in monkeys at the Oregon National Primate Research Center.

It involves swapping the mitochondrial DNA in a mother's egg with mitochondrial DNA from another woman. That swapping could bypass mutations that cause damaging conditions like diabetes and dementia.

Doctor Shoukhrat Mitalipov says he's successfully demonstrated the procedure in human cells -- and he wants the FDA to allow clinical trials in people.

"It might take probably at least two or three years before we start these clinical trials. But how long the FDA would like us to follow up this case is unclear at this point."

The Center for Genetics and Society says this kind of genetic engineering has been ruled off-limits because it could be used for genetic enhancement. For example, improving a child's IQ or physical appearance.

The Center also warns that a mistake could introduce a new genetic disease into the population.

The research is published in the journal Nature.

See more here:
OHSU Unveils A Potential Breakthrough In Gene Therapy